BALDR: A Web-based platform for informed comparison and prioritization of biomarker candidates for type 2 diabetes mellitus

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Novel biomarkers are key to addressing the ongoing pandemic of type 2 diabetes mellitus. While new technologies have improved the potential of identifying such biomarkers, at the same time there is an increasing need for informed prioritization to ensure efficient downstream verification. We have built BALDR, an automated pipeline for biomarker comparison and prioritization in the context of diabetes. BALDR includes protein, gene, and disease data from major public repositories, text-mining data, and human and mouse experimental data from the IMI2 RHAPSODY consortium. These data are provided as easy-to-read figures and tables enabling direct comparison of up to 20 biomarker candidates for diabetes through the public website https://baldr.cpr.ku.dk.

Cite

CITATION STYLE

APA

Lundgaard, A. T., Burdet, F., Siggaard, T., Westergaard, D., Vagiaki, D., Cantwell, L., … Brunak, S. (2023). BALDR: A Web-based platform for informed comparison and prioritization of biomarker candidates for type 2 diabetes mellitus. PLoS Computational Biology, 19(8 August). https://doi.org/10.1371/journal.pcbi.1011403

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free